| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Biocartis Group NV (BR: BCART)
BCART Technical Analysis
5
| As on 11th Jul 2023 BCART SHARE Price closed @ 0.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.66 & Strong Sell for SHORT-TERM with Stoploss of 2.34 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BCARTSHARE Price
| Open | 0.36 | Change | Price | % |
| High | 0.36 | 1 Day | -0.01 | -2.78 |
| Low | 0.34 | 1 Week | -0.01 | -2.78 |
| Close | 0.35 | 1 Month | -0.20 | -36.36 |
| Volume | 74420 | 1 Year | -2.60 | -88.14 |
| 52 Week High 2.95 | 52 Week Low 0.34 | ||||
BR Belgium Most Active Stocks
| BOTHE | 0.29 | 70.59% |
| ABI | 50.92 | 0.47% |
| ACPH | 0.89 | 0.00% |
| KBC | 66.02 | 2.36% |
| UMI | 26.30 | 2.94% |
| PROX | 7.06 | 0.14% |
| OPTI | 0.02 | % |
| BPOST | 4.33 | 3.10% |
| WDP | 26.58 | 1.22% |
| EURN | 14.06 | 2.33% |
BR Belgium Top Gainers Stocks
BR Belgium Top Losers Stocks
| BCART Daily Charts |
BCART Intraday Charts |
Whats New @ Bazaartrend |
BCART Free Analysis |
|
|
BCART Important Levels Intraday
| RESISTANCE | 0.39 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.37 |
| RESISTANCE | 0.36 |
| SUPPORT | 0.34 |
| SUPPORT | 0.33 |
| SUPPORT | 0.32 |
| SUPPORT | 0.31 |
BCART Forecast April 2024
| 4th UP Forecast | 2.59 |
| 3rd UP Forecast | 1.87 |
| 2nd UP Forecast | 1.43 |
| 1st UP Forecast | 0.98 |
| 1st DOWN Forecast | -0.28 |
| 2nd DOWN Forecast | -0.73 |
| 3rd DOWN Forecast | -1.17 |
| 4th DOWN Forecast | -1.89 |
BCART Weekly Forecast
| 4th UP Forecast | 0.93 |
| 3rd UP Forecast | 0.74 |
| 2nd UP Forecast | 0.63 |
| 1st UP Forecast | 0.51 |
| 1st DOWN Forecast | 0.19 |
| 2nd DOWN Forecast | 0.07 |
| 3rd DOWN Forecast | -0.04 |
| 4th DOWN Forecast | -0.23 |
BCART Forecast2024
| 4th UP Forecast | 5.46 |
| 3rd UP Forecast | 3.82 |
| 2nd UP Forecast | 2.81 |
| 1st UP Forecast | 1.79 |
| 1st DOWN Forecast | -1.09 |
| 2nd DOWN Forecast | -2.11 |
| 3rd DOWN Forecast | -3.12 |
| 4th DOWN Forecast | -4.76 |
Biocartis Group NV ( BR Belgium Symbol : BCART )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BCART Business Profile
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan 11 B, Mechelen, Belgium, 2800
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service